New cancer drug shows promise in early human trial
NCT ID NCT03573310
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested a new oral drug, JNJ-64619178, in 114 people with advanced cancers (including solid tumors, lymphoma, and myelodysplastic syndromes) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug might control tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JNJ-64619178 (a drug that blocks a protein called PRMT5, which may slow cancer growth)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced cancers that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 114 participants, so the drug may not prove effective or safe enough for further testing. Side effects, including serious toxicities, are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Carmel Medical Center
Haifa, 34362, Israel
-
Clinica Univ. de Navarra
Pamplona, 31008, Spain
-
Florida Specialist and Cancer Institute
Sarasota, Florida, 34232, United States
-
Goethe Universität Frankfurt
Frankfurt am Main, 60590, Germany
-
Hadassah Medical Center
Jerusalem, 9112001, Israel
-
Hosp Clinico Univ de Salamanca
Salamanca, 37007, Spain
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp Univ Vall D Hebron
Barcelona, 08035, Spain
-
Hosp. Univ. Germans Trias I Pujol
Badalona, 08916, Spain
-
Hosp. Virgen Del Rocio
Seville, 41013, Spain
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Princess Margaret Cancer Centre University Health Network
Toronto, Ontario, M5G1Z5, Canada
-
St. Paul's Hospital
Vancouver, British Columbia, V6E 1M7, Canada
-
Tel Aviv Sourasky MC
Tel Aviv, 6423906, Israel
-
Universitaetsklinikum Duesseldorf
Düsseldorf, 40225, Germany
-
Universitaetsklinikum Leipzig
Leipzig, 04103, Germany
-
University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030, United States